HERON THERAPEUTICS, INC. /DE/ Available-for-sale Securities, Amortized Cost Basis
HERON THERAPEUTICS, INC. /DE/ (HRTX) had Available-for-sale Securities, Amortized Cost Basis of $300.62 million as of 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-02-22
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $300.62M.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $67.41M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $27.81M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $8.49M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-12-31 | $300.62M 10-K · filed 2019-02-22 | |
| 2018-03-31 | $67.41M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $27.81M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $8.49M 10-Q · filed 2017-11-06 | |
| 2017-06-30 | $83.99M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $122.15M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $37.74M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $56.03M 10-K · filed 2017-02-23 | $57.03M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |